Is TB-500 Legal in Oregon? Federal Law, State Rules, and How to Get It

What Is TB-500 and Why Does Its Legal Status Matter?

TB-500 is a synthetic 43-amino-acid peptide derived from thymosin beta-4, an endogenous protein found in nearly all human and animal cells. Research has focused on its potential role in tissue repair, actin polymerization, and modulation of inflammatory signaling. A 2010 review in Annals of the New York Academy of Sciences described thymosin beta-4 as "a multifunctional tissue repair and tolerance factor" with activity across cardiac, ocular, and dermal injury models.

The clinical and legal situations are linked. Because TB-500 has no FDA-approved drug application, every pathway to lawful human use runs through either the compounding framework or an unapproved-drug exception. Getting that framework wrong exposes patients, prescribers, and pharmacies to federal enforcement.

Thymosin Beta-4 vs. TB-500: A Critical Distinction

Thymosin beta-4 is the full endogenous protein. TB-500 is the Ac-LKKTETQ peptide fragment (approximately residues 17 to 23) that is believed to carry most of the parent molecule's biological activity. This distinction matters legally: FDA's enforcement actions and bulk-substance determinations reference "thymosin beta-4," and the agency has consistently treated TB-500 as falling under that designation because it is derived from and functionally overlaps with the parent compound.

Why Patients Are Seeking It

Interest in TB-500 has grown alongside broader telehealth adoption of peptide therapies. Patients recovering from musculoskeletal injuries, athletes seeking accelerated tissue repair, and individuals with chronic inflammatory conditions have pursued it. A 2022 PubMed-indexed preclinical study demonstrated that thymosin beta-4 significantly reduced inflammatory markers and promoted cardiomyocyte survival in a murine ischemia model, fueling patient interest despite the absence of completed Phase 3 human trials.

The Federal Regulatory Framework That Governs TB-500

Understanding whether TB-500 is legal in Oregon starts at the federal level, because FDA's authority over drug compounding is national and preempts conflicting state rules.

FDA's Unapproved Drug Status

TB-500 has no approved New Drug Application (NDA) and no Investigational New Drug (IND) exemption for general clinical use. Under 21 U.S.C. § 331, introducing an unapproved new drug into interstate commerce is prohibited. The FDA's current guidance on human drug compounding, published under the Drug Quality and Security Act (DQSA) of 2013, establishes the only lawful pathways for compounding drugs that lack an approved application.

The 503A/503B Compounding Distinction

The DQSA created two categories of compounding pharmacy:

503A pharmacies compound drugs for individual patients based on valid prescriptions. They may use bulk drug substances only if those substances appear on an FDA-nominated and approved list, or if they meet specified criteria.

503B outsourcing facilities compound larger quantities without patient-specific prescriptions. They face stricter current Good Manufacturing Practice (cGMP) requirements and may only use bulk substances that FDA has specifically authorized.

FDA's current 503A bulks list and its interim policies are publicly accessible on the agency's compounding portal. Thymosin beta-4 and its fragments, including TB-500, are placed in what FDA calls the "Category 2" group, meaning the agency has evaluated the substance and determined it should not be used in compounding under 503A. That evaluation was formalized in agency guidance documents beginning in 2019 and updated through 2023.

What "Category 2" Means in Practice

Category 2 status does not make TB-500 a controlled substance. There is no Schedule I through V designation for peptides like this one. Possession of TB-500 for personal use is not a criminal offense under federal drug scheduling law. The practical consequence of Category 2 status is that licensed 503A compounding pharmacies cannot legally fill prescriptions for it, and 503B outsourcing facilities cannot legally manufacture it for distribution.

A licensed prescriber can still write a prescription. The pharmacist simply has no legal route to fill it through normal compounding channels while the Category 2 designation remains in force.

Oregon-Specific Law: What the State Does and Does Not Regulate

Oregon has no statute that independently bans TB-500 or any other specific peptide by name. State authority over compounding operates through the Oregon Board of Pharmacy (OBP), which licenses pharmacies and enforces state standards for compounding practices.

Oregon Board of Pharmacy Standards

The OBP requires all compounding pharmacies operating in Oregon to comply with USP <797> standards for sterile compounding and with OAR Chapter 855, Division 019, which governs pharmacy compounding. The Board has not issued a state-level exemption or special category for thymosin beta-4. Oregon pharmacies that compound for human use are expected to operate within the federal 503A/503B framework.

The OBP's compounding guidance page confirms alignment with FDA requirements and does not list any state-specific carve-outs for unapproved peptides.

Oregon Medical Practice Act and Prescriber Authority

Under ORS 677.085, a licensed Oregon physician may prescribe any substance for a legitimate medical purpose under the standard of care, including substances that are not FDA-approved, provided a valid prescriber-patient relationship exists. This is the "practice of medicine" authority that exists in every state.

The framework works as follows for TB-500 in Oregon:

1. A physician determines that TB-500 is clinically appropriate for a specific patient.
2. The physician writes a valid prescription.
3. The prescription cannot be filled by a standard 503A pharmacy because of FDA's Category 2 designation.
4. The physician may obtain TB-500 directly from a licensed drug manufacturer for in-office use under certain conditions, but no licensed US manufacturer currently produces an injectable TB-500 for human administration with full cGMP compliance.
5. The patient is left with no legally compliant dispensing pathway through conventional Oregon-licensed channels at this time.

This four-step dead end is the core of TB-500's gray-area status in Oregon. The prescription can be written; it simply cannot be filled through any currently compliant channel.

Does Oregon Have a Research-Chemical Exemption?

No. Oregon follows federal law in treating substances sold as "research chemicals" for human use as unapproved drugs. The label "for research use only" on a vendor's website does not change the legal character of the product if it is sold with implied human-use intent or if a patient administers it to themselves. FDA has issued multiple warning letters to peptide and research-chemical vendors, explicitly stating that labeling a product "not for human use" does not exempt it from drug adulteration and misbranding provisions under 21 U.S.C. § 351 to 352.

How to Get TB-500 in Oregon: Realistic Pathways

Given the regulatory constraints above, patients in Oregon have a small number of pathways, each with distinct risk profiles.

Pathway 1: Telehealth Prescription Through a Compliant Compounding Pharmacy

Some compounding pharmacies have sought to operate in a compliance window by arguing that FDA's Category 2 guidance is non-binding and that the substance technically remains on the "nominated" list pending final rulemaking. A small number of 503A pharmacies continue to compound thymosin beta-4 products under this interpretation, accepting that they carry regulatory risk.

A board-certified physician practicing via telehealth in Oregon may evaluate a patient, determine clinical appropriateness, and transmit a prescription to one of these pharmacies. This pathway is technically available but carries real regulatory exposure for the pharmacy and, to a lesser degree, for the prescribing physician.

Patients pursuing this route should verify that the compounding pharmacy:

• Holds an active 503A license in its home state
• Follows USP <797> sterile compounding standards
• Can provide a certificate of analysis (CoA) from an independent third-party lab
• Ships to Oregon (cross-state compounded prescriptions are permitted under federal law for individual patient orders)

Pathway 2: Clinical Trial Enrollment

ClinicalTrials.gov currently lists several active or recruiting trials involving thymosin beta-4 or analogous peptides for conditions including dry eye disease and cardiac repair. Patients who qualify for an IND-protected trial receive the drug lawfully and under physician supervision. Oregon Health and Science University (OHSU) and other Portland-area academic centers periodically participate in peptide research protocols.

Pathway 3: Compounded Veterinary Formulations (Not Recommended for Human Use)

TB-500 is widely used in equine and canine sports medicine, and many veterinary compounding pharmacies produce it legally for animal patients. Patients sometimes obtain veterinary formulations for self-administration. This practice carries serious risks: veterinary-grade compounds are not manufactured to human sterility standards, dosing differs substantially, and self-injection of non-sterile peptides can cause severe infections. This pathway is not recommended under any circumstances.

Pathway 4: FDA-Cleared Research Chemical (Not for Human Use)

Non-GMP TB-500 is available from numerous online vendors. Purchasing it is not a federal crime for personal possession. Administering it is not criminally prosecuted under current federal enforcement priorities. This does not make it legal for human use. It means enforcement is focused elsewhere. Patients who proceed this way have no physician oversight, no sterility guarantee, and no recourse if the product is mislabeled. A 2020 analysis of commercially available peptide products found that 37% of samples tested by mass spectrometry contained either the wrong peptide, the wrong concentration, or detectable impurities.

What Oregon Physicians and Telehealth Providers Need to Know

Oregon's telehealth framework, established under ORS 677.097 and expanded by emergency provisions that became permanent in 2021, allows physicians to establish valid prescriber-patient relationships via synchronous video consultation. A physician who determines that a compounded peptide is medically appropriate may prescribe through this channel.

The critical obligations for Oregon-licensed prescribers are:

Documenting Clinical Justification

Oregon's Medical Practice Act requires that prescriptions for non-FDA-approved substances be supported by documented clinical reasoning in the patient's chart. The prescriber should record the specific indication, why FDA-approved alternatives were considered and found insufficient, and what risk-benefit analysis supports the decision.

Staying Current on FDA Guidance Updates

FDA's bulk-substance list is not static. The agency has moved substances between categories as evidence accumulates. The FDA's compounding page for bulk drug substances used under Section 503A is updated regularly and should be reviewed before any new prescription is initiated.

As of the date of this article's last review (January 2025), thymosin beta-4 remains in Category 2. If FDA reclassifies it to the affirmative 503A list following a completed evaluation, the compounding pathway would open substantially.

Liability Considerations

Prescribing a substance from a pharmacy operating outside FDA compliance creates malpractice exposure. Oregon Medical Board guidance on prescribing non-FDA-approved substances (OAR 847-010-0035) requires that prescribers be able to demonstrate that their decision met the standard of care. Several peptide-prescribing physicians in other states have faced board complaints following patient adverse events tied to compounded peptides from non-compliant pharmacies.

The Science Behind TB-500: What Human Data Actually Exists

Patients ask about TB-500 because the preclinical data is genuinely compelling. The legal status should be understood alongside the evidentiary picture.

Preclinical Evidence

Thymosin beta-4 has been studied extensively in animal models. A 2004 paper in Nature Medicine (Bock-Marquette et al.) demonstrated that systemic delivery of thymosin beta-4 reactivated dormant epicardial progenitor cells and promoted cardiac repair after myocardial infarction in adult mice. Wound-healing studies in rodent models consistently show accelerated dermal repair and reduced fibrosis.

Human Clinical Data

Human data is sparse. A Phase 2 trial of RGN-352 (injectable thymosin beta-4) in acute myocardial infarction (NCT01311518) was completed but results were not published in a peer-reviewed journal accessible through PubMed as of the most recent search. RegeneRx Biopharmaceuticals, the company that developed RGN-series thymosin beta-4 products, reported tolerability data showing no dose-limiting toxicities at doses up to 1,260 mg total across the treatment period, but efficacy endpoints were not met with statistical significance.

A Phase 2 trial of RGN-259 (thymosin beta-4 eye drops) for dry eye syndrome (NCT02596763) showed statistically significant improvements in total ocular surface disease index scores versus placebo (P<0.05) in a 150-patient cohort.

This pattern, promising in animals, mixed and limited in humans, is precisely the evidentiary gap that keeps TB-500 off FDA's approved list and in regulatory limbo.

Dosing Ranges Used in Practice

Compounding pharmacies that have dispensed thymosin beta-4 typically use protocols in the range of 2 mg to 5 mg administered subcutaneously two to three times per week during a loading phase of four to six weeks, followed by a maintenance dose of 2 mg once or twice per week. These dosing schemas are not derived from completed Phase 3 trials. They are extrapolated from preclinical data and the limited Phase 2 safety observations above. Patients should treat any published "standard protocol" as clinical hypothesis rather than established medicine.

Oregon-Specific Resources for Patients and Providers

Patients in Oregon who want to explore TB-500 through a compliant channel should start with the following:

• Oregon Board of Pharmacy: (971) 673-0001 or pharmacy.oregon.gov. The Board can confirm whether a specific compounding pharmacy is licensed to ship into Oregon.
• Oregon Medical Board: (971) 673-2700. Providers can request informal guidance on whether a specific prescribing decision meets OAR 847-010-0035 standards.
• FDA MedWatch: Adverse events from compounded peptides should be reported at fda.gov/safety/medwatch. This reporting helps FDA's post-market surveillance and may eventually support reclassification decisions.
• ClinicalTrials.gov: Patients interested in access through a trial can search "thymosin beta-4" filtered by "Oregon" or "recruiting" status at clinicaltrials.gov.